Limited Spread of Penicillin-Nonsusceptible Pneumococci, Skåne County, Sweden by Melander, Eva et al.
In response to increasing frequencies of penicillin-non-
susceptible pneumococci (PNSP), for which the MIC of
penicillin was ≥0.12 mg/L, in Skåne County, southern
Sweden, national recommendations were initiated in 1995
to limit the spread of pneumococci with high MICs (≥0.5
mg/L) of penicillin (PRP), especially among children of pre-
school age. Traditional communicable disease control
measures were combined with actions against inappropri-
ate antimicrobial drug use. During the first 6 years that
these recommendations were applied in Skåne County, the
average frequency of penicillin-resistant pneumococci has
been stable at ≈2.6%, as has the average PNSP frequency
(7.4%). However, PNSP have been unevenly distributed in
the county, with the highest frequencies in the southwest.
Simultaneously, the rate of antimicrobial drug use for chil-
dren <6 years of age was reduced by 20%. Thus the
spread of PNSP between and within the municipalities in
the county has been limited.
I
ncreasing frequencies of penicillin-nonsusceptible
pneumococci (PSNP) (MIC of penicillin ≥0.12 mg/L)
became a worldwide problem in the 1980s (1,2). The rapid
increase in frequency is likely caused by intercontinental
spread of a few PNSP clones for which MICs of penicillin
are high (3–6). For a long period, very low PNSP
frequencies were noted in Sweden (2%–3%) (7). However,
in the early 1990s, the incidence of PNSP increased from
8% to 10% in Skåne, the southernmost county, while the
rest of the country reported unchanged low frequencies
(8–10). When considered from the perspective of
international experience, in which the rate of PNSPrapidly
increased when this level of resistance was reached (11),
the increasing frequencies of PNSPin Skåne County led to
the formation of an expert committee, appointed by the
National Board of Health and Welfare. This committee
proposed a national strategy in 1995, based on reducing
unnecessary use of antimicrobial agents and applying
infection control measures to limit the more immediate
spread of PNSP for which MICs of penicillin were high
(≥0.5 mg/L, PRP), especially in preschool children ages 1
to 6 years. In 1996, infection and carriage with PRP
became notifiable by the Swedish Communicable Disease
Act. The reasons to choose MIC ≥0.5 mg/L as a limit for
intervention were that epidemiologic data on pneumococci
suggested that an increased prevalence of strains for which
the MIC of penicillin was ≥1.0 mg/L most often was
caused by spread of a few already resistant clones, so that
those strains could lead to treatment failures, and that those
strains were relatively rare in Sweden in 1994 (12). Since
the Etest can be hard to interpret, MIC ≥0.5 mg/L was
chosen so strains for which the MIC of penicillin was 1.0
mg/L would not be missed. The decision of whether to
follow the recommendations of the expert committee is
made by each county department for communicable
disease control. The recommendations were strictly
applied in Skåne County (South Swedish Pneumococcal
Intervention Project, SSPIP), while some Swedish
counties either did not follow the recommendations at all
or only applied parts of the recommendations. For a long
period, Skåne County had the highest use of antimicrobial
agents in Sweden, especially of macrolides and broad-
spectrum antibiotics (13), and in the SSPIP traditional
communicable disease control measures are combined
with actions aimed at reducing the use of antimicrobial
drugs. Experiences from the first 2 years of the SSPIPfrom
parts of Skåne County have previously been reported
(14–17). For example, data on individual risk factors for
carriage of PNSP have been evaluated. We discuss the
overall results of the SSPIP and evaluate the effects of the
recommendations in Skåne County during the first 6 years
they were implemented.
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Study Area
On January 1, 2000, the population of Skåne County
was 1,129,424 inhabitants; 93,051 were <6 years of age.
The county is divided into 33 municipalities. The largest
municipality, Malmö, had 259,579 inhabitants and of
those, 20,325 were <6 years of age. The smallest munici-
pality had 6,745 inhabitants; 581 were <6 years. During
the study period, ≈76% of the children 1 to 6 years of age
were enrolled in day care. 
SSPIP
The principles of the SSPIP have been described
earlier (16). In brief, all persons in Skåne County with a
culture that yields penicillin-nonsusceptible pneumococci
with an MIC ≥ 0.5mg/Lfor penicillin (PRP), regardless of
resistance to any other antibiotics, have since 1995 been
reported to the Regional Center of Communicable Disease
Control (CCDC). Whenever a person with a clinical
infection caused by PRP (index case-patient) is identified,
nasopharyngeal cultures are obtained from family
members and other close contacts to identify
asymptomatic PRP carriers (contact case-patients). All
carriers are followed weekly with nasopharyngeal
cultures at the local primary health care center until two
consecutive cultures that yield no growth of PRP (PRP-
negative) have been obtained. If the index case is in a
child attending any form of group day care,
nasopharyngeal cultures are obtained from the other
children and staff members at that day care group.
Preschool children are restricted from attending day care
until they are PRP-negative. In selected cases, eradication
therapy with antimicrobial drugs is considered after 2 to 3
months of carriage, or earlier when strong social reasons
exist (18). 
Microbiologic Methods
The pneumococcal strains considered in this study were
recovered from cultures analyzed at the Departments of
Clinical Microbiology in Lund, Malmö, Helsingborg, and
Kristianstad from July 1, 1995, through June 30, 2001.
These four laboratories served the entire population of
Skåne County during the study period. The specimen were
cultured on blood agar plates, and the isolates were identi-
fied as Streptococcus pneumoniae on the basis of colony
morphology and susceptibility to optochin (19). The
strains were screened for penicillin-resistance by using the
disk-diffusion method, according to the Swedish
Reference Group for Antibiotics (SRGA). The strains were
inoculated onto Iso Sensitest agar (Oxoid Ltd,
Basingstoke, UK), supplemented according to the recom-
mendations, and the antibiotic disks (Oxoid Ltd) were
applied. Inhibition zones were read to the nearest millime-
ter and interpreted according to SRGAguidelines (20). For
pneumococci with an oxacillin 1 µg inhibition zone <20
mm, the MIC of penicillin was determined by the Etest
(AB Biodisk, Solna, Sweden) (21). The susceptibility to
other antimicrobial agents (erythromycin, tetracycline,
trimethoprim-sulfamethoxazole, and clindamycin) was
determined by using the disk diffusion method (10).
Strains from each patient were registered only once per
season, even if multiple cultures were positive for pneu-
mococci. Whether the strains were recovered at a visit to
the doctor or by contact tracing or screening was noted.
Serotyping to the group level was performed by the quel-
lung reaction, by using antisera from the Statens
Seruminstitut, Copenhagen, Denmark (19). 
Antimicrobial Drug Use
Data were collected regarding antimicrobial drug pre-
scriptions for outpatient care, served at Swedish pharma-
cies from July 1, 1995, through June 30, 2001, that were
issued for children ages <6 years who lived in Skåne
County; these data were obtained from the Corporation of
Swedish Pharmacies, which owns all Swedish pharmacies
and collects and compiles information on all drugs sold in
the country (13). The municipality of the patient was reg-
istered. The prescribed antimicrobial agents were given as
prescriptions per 1,000 inhabitants ages <6 years per sea-
son, and all prescriptions of phenoxymethylpenicillin
(PcV), ampicillin/amoxicillin (including amoxicillin+
clavulanic acid), cephalosporins, trimethoprim-
sulfamethoxazole, macrolides, clindamycin, and other
antimicrobial drugs (grouped together) were registered. 
Results
During the project, the frequency of PNSPcarriers from
clinical nasopharyngeal cultures has been evaluated.
Cultures taken at contact tracing were excluded. From July
1, 1995, until June 30, 2001, the average frequency of
PNSP carriers has been stable, approximately 7.4% (2,750
PNSP/34,745 pneumococci) (Figure 1). The highest
frequencies (8.1%) were seen in 1997 to 1998. During the
6 years of the recommendations, the levels of PNSP have
been unevenly distributed over the county; higher and
stable levels were found in the city of Malmö in the
southwestern part of the county, (11.3%, 976 PNSP/8,651
pneumococci) and lower, but stable, levels were found in
the northeastern part of the county (4.3%, 395 PNSP/9,109
pneumococci). The frequency of PNSP among invasive
pneumococcal strains (blood and cerebrospinal fluid
cultures) in Skåne County has been low, ≥2.5 % (22
PNSP/858 pneumococci). As with the PNSP in
nasopharyngeal cultures, the highest frequencies of
invasive PNSP were seen in 1997 to 1998. 
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(that is, the number of clinical case-patients with a culture
with growth of PRP, divided by the number of pneumococ-
ci found in nasopharyngeal cultures) has been rather stable
since the start of the project, ≈2.6% (905 PRP/34,745
pneumococci) (Figure 1). In the southwestern part of the
county, in the cities of Malmö and Lund and surrounding
municipalities, where most cases were found, PRP have
been constantly present. However, in several of the small-
er municipalities, PRP were prevalent during one or two
seasons but then disappeared. In two municipalities, both
situated in the northeast, no cases of PRP infection have
been found. The proportion of cases with PRP with high
MICs (≥2 mg/L) of penicillin has not increased during the
6 years (Table). Carriers of PRP with MIC ≥4.0 mg/L have
all been adopted children or immigrants from Eastern
Europe or from countries outside Europe.
During the 6-year period, 2,269 PRP carriers (1,865
persons) have been registered at the CCDC in Skåne
County. Of the 2,269 PRP carriers, 40% were index case-
patients, and 60% were contacts. Few contact cases have
been found in persons at the extremes of ages (≤1 year and
>65 years). The number of contact cases per index patients
in children <6 years of age has, on an average, been 1.6
(1.1 to 2.2 per season) and has not increased. The index
patients have most often been found through positive
nasopharyngeal cultures, and only a minority (n = 13,
1.4%) have been found through positive blood or cere-
brospinal fluid cultures. More men carried PRP overall,
but in the group ages 18 to 64 years, PRP carriage was
more common among women. A clear seasonal variation
in the incidence of PRP was found; considerably more
cases occurred during the winter months (October–March)
than during summer. The median duration of PRP carriage
was 21 days (range 2–368 days); 1,704 (75%) of the PRP
patients were children 1 to 6 years of age. Seventy-one
percent of these children attended day care centers; 6%
attended family day care, and 23% were cared for at home.
The other contacts have primarily been siblings, parents, or
grandparents of young children. 
Two hundred and twenty-seven children with a clinical
culture showing growth of PRP, led to screening of chil-
dren and staff at 227 of the county’s 1,250 day care cen-
ters. The number of contact cases per index case-patient
among all children attending these day care centers has, on
an average, been 3.46 (2.6–4.2 per season) and has not
increased, and the number of contact cases in each day care
center has varied from 0 to 25 (median 2). In 24% of the
day care center interventions, no contact cases were found.
In 45 of the 227 day care centers, more than one PRP
serotype was discovered, and 65 day care centers have
been investigated twice or more (median 2, range 2–6).
Twenty-two of these day care centers had two outbreaks
with the same serotype within 6 months. Most of the day
care interventions took place in the southwestern part of
the county. Only 20 of all screened staff at day care centers
were PRP-positive. 
Serotyping to the group level was performed for 2,131
(94%) of the 2,269 PRP strains. Twenty-five serotypes of
PRP were found. Six serotypes comprised 93% of the
strains (serotypes 9, 19, 6, 23, 15, 14). The most prevalent
strain, serotype 9, represented an average of 48% of the
PRP strains (37%–66% per season). This strain has spread
over the county from municipality to municipality in a
clear pattern, whereas the other common serotypes have
spread more randomly. 
The use of antimicrobial agents in outpatient care in
Skåne County decreased from the first to the last season in
all age groups, but especially in children aged <6 years
(Figure 2). The main reduction among children ages <6
years was caused by a decrease in number of prescriptions
for phenoxymethylpenicillin, and the use of macrolides
was reduced by 50%. Even though the decreased use of
antimicrobial drugs was seen in all municipalities, the
municipalities with the highest utilization in 1995–1996
still had the highest use in 2000–2001. Those municipali-
ties were all located in the southwestern part of the county.
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Figure 1. Frequency of penicillin-nonsusceptible pneumococci
with MIC for penicillin ≥0.12 mg/L and ≥0.5 mg/L per season in
Skåne County, Sweden, expressed in percentage of all pneumo-
cocci from clinical nasopharyngeal cultures.
Table. Distribution of MICs of penicillin for all registered PRP 
cases in Skåne County per season
a 
Season  0.5 mg/L, n (%)  1.0 mg/L, n (%)  >2.0 mg/L, n (%) 
1995–1996  217 (33)  290 (44)  151 (23) 
1996–1997  132 (36)  140 (37)  102 (27) 
1997–1998  189 (42)  214 (47)  52 (11) 
1998–1999  124 (46)  140 (52)  4 (2) 
1999–2000  183 (59)  111 (35)  18 (6) 
2000–2001  124 (62)  75 (38)  0 
aPRP, pneumococci with MIC >0.5 mg/L. Discussion 
In Skåne County, where PNSP (pneumococci with an
MIC for penicillin ≥0,12 mg/L) have been prevalent for
>10 years, the frequency of PNSP in clinical nasopharyn-
geal cultures (cultures taken at contact tracing excluded)
remained at the same level in 2000 to 2001 as in 1995 to
1996, on average, 7.4%. In the city of Malmö, where the
spread of PNSP appears to have started, the average level
of PNSP has been higher (11.3%) during the project peri-
od. In contrast, the average level of PNSP remained low
(4.3%) during the study period in the northern and eastern
parts of the county. Furthermore, the number of PRP con-
tact cases per index case among children attending day
care centers did not increase during the 6-year period.
These data indicate that the rapid spread of PNSP that
started in the southwestern part of the county in the begin-
ning of the 1990s (8,9) has been limited. These results are
unique in comparison with experience in other countries,
where PNSP rates have rapidly increased after reaching an
8% PNSP level (11). The proportion of contacts with PRP
with high MICs of the PNSP in Skåne County has not
increased during the 6-year period, contrary to results from
most other countries, which report increasing frequencies
of PNSP with high MICs (22,23). 
One of the project’s aims was to decrease unnecessary
use of antimicrobial agents, especially of macrolides and
trimethoprim-sulfamethoxazole, which in studies have
been shown to promote spread of PNSP (17,24–27).
During the study period, the use of antimicrobial drugs
decreased in all municipalities in the county, and the
decrease was most prominent in children ages <6 years. In
this age group, the use of macrolides was cut in half. The
use of long-acting macrolides has been extremely low and
has comprised <3% of the total use of macrolides among
children. Even though the use of antimicrobial agents
decreased in all municipalities of Skåne County, those with
high usage in 1995 to 1996 also had high usage in 2000 to
2001, and those with low usage in 1995 to 1996 had an
even lower usage in 2000 to 2001. Mirroring the use of
antimicrobial agents, the occurrence of PNSP has been
unevenly distributed in the county, with constant high rates
in the southwestern part and low levels in the northern and
eastern parts. In cities in the northeastern parts and in the
smaller municipalities, with lower antimicrobial agent use,
single outbreaks have occurred without any more cases
being reported later. A possible explanation for this might
be that municipalities in which antibiotics are frequently
used have a higher risk of spreading PNSP in the
community, as indicated by previously published data
from the project as well as by other studies (17,24,28,29). 
Many PRP serotypes were found in the county during
the six seasons. However, one serotype, serotype 9, has
dominated during all six seasons and has spread in a clear
pattern from municipality to municipality throughout the
county (15), while other strains have spread more random-
ly in time and geographically. Why this strain has been
persistently present for such a long time is unclear. 
We chose to present the figures for the frequency of
PNSP in clinical cultures over time, excluding cultures
taken at contact tracing, since the contacts were not found
at random, but rather represented a selected population
around an index patient. The exclusion of cultures taken at
contact tracing ought to give more fair figures when com-
paring data from the study period with the “resistance sit-
uation” before the project started or with data from other
studies. The possibility of excluding all cultures taken at
contact tracing retrospectively was not 100% guaranteed,
but cultures taken at day care center screenings were easi-
ly found and excluded. The rest of the cultures obtained
because of contact tracing constituted only a small propor-
tion of cultures, and thus they should not be a source of
error. 
Although the indication for nasopharyngeal sampling
was not changed during the study period, the number of
obtained samples has decreased since the start of the
project. However, the number of nasopharyngeal cultures
increased in 1995 to 1996 compared to 1993 to 1994. One
possible explanation for this might be that the health
authorities encouraged doctors to take nasopharyngeal
samples more frequently during the first years of the
project. 
Exactly comparable data on PNSP frequencies from
other Swedish counties or comparable survey data
(nasopharyngeal cultures) from other countries are hard to
find. However, since 1996, Swedish law has mandated the
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Figure 2. Use of antimicrobial agents in outpatient care among
children ages <6 years in Skåne County, Sweden, expressed in
prescriptions per 1,000 inhabitants per season. reporting of all PRP strains to the Swedish Institute for
Infectious Disease Control. Data from this national regis-
ter contains information on reported PRP from all over
Sweden from 1997 to 2002. Of all reported PRP, the PRP
from Skåne County comprised 40% in 1997, but only 10%
in 2002 (Figure 3). Furthermore, the recommendations are
strictly applied in Skåne County, while some Swedish
counties either do not follow the recommendations at all or
only apply parts of the recommendations. In some coun-
ties, where the recommendations were not applied or not
as strictly applied as in Skåne County, the frequencies of
PRP have increased from 2000 to 2002 (30,31). Moreover,
according to data from the annual Resistance Surveillance
and Quality Control Programme, the frequency of PNSPin
clinical nasopharyngeal cultures in Sweden has increased
from 3.8% in 1994 to 6.2% in 2002 (30,32). In addition,
the frequency of PNSP among invasive pneumococcal
strains in Sweden has, on average, increased from 1.4% in
1999 to 2.4% in 2002 (30,33), but the frequency of inva-
sive PNSP during the same period in Skåne County has
been approximately 2.5% and stable. The numbers of inva-
sive PNSP isolates in Skåne County are very low, and
therefore drawing any reliable conclusions from these data
is difficult. However, the frequency of PNSP has not
increased, as it has in most other countries, and the trends
of invasive PNSPseem to follow the trends for PNSPfrom
nasopharyngeal cultures. Compared to the other Nordic
countries, who still report low frequencies of invasive
PNSP, Sweden has had the lowest frequencies of invasive
PNSP between 1999 and 2002 (33).
Although the frequencies of PNSP in Skåne County
were not reduced, the spread of PNSP seems to have been
limited. Whether this is a result of the actions of the SSPIP
among children or of the decreased use of antibiotics in the
county, or both, is impossible to tell since these actions
were started simultaneously. In other countries, actions
against unnecessary use of antimicrobial drugs has been
the only measure of combating the spread of PNSP, in
most cases with little success, probably in part because the
actions have been initiated in a much later phase, when fre-
quencies of PNSP were higher (34–37). Still, further
efforts are necessary to reduce the prescribing of antimi-
crobial agents in the southwestern areas, since the use of
antimicrobial agents is still high there and poses the great-
est risk factor for PNSP carriage.
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